Virtu Financial LLC Purchases 8,282 Shares of Illumina, Inc. (NASDAQ:ILMN)

Virtu Financial LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 419.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,256 shares of the life sciences company’s stock after purchasing an additional 8,282 shares during the quarter. Virtu Financial LLC’s holdings in Illumina were worth $1,070,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Illumina by 0.4% during the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after acquiring an additional 66,528 shares in the last quarter. Edgewood Management LLC lifted its holdings in shares of Illumina by 4.6% during the 4th quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock valued at $957,762,000 after purchasing an additional 302,222 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of Illumina by 8.7% in the 1st quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock valued at $787,725,000 after purchasing an additional 460,649 shares during the period. WCM Investment Management LLC increased its stake in Illumina by 2,232.3% during the 1st quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock worth $463,760,000 after purchasing an additional 3,232,418 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after buying an additional 204,043 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 0.6 %

ILMN stock opened at $130.97 on Thursday. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $148.19. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $20.86 billion, a price-to-earnings ratio of -16.07 and a beta of 1.15. The business’s fifty day moving average price is $124.62 and its two-hundred day moving average price is $120.62.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the firm earned $0.32 earnings per share. Illumina’s revenue for the quarter was down 5.4% compared to the same quarter last year. On average, equities analysts anticipate that Illumina, Inc. will post 3.62 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Scotiabank lowered their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. UBS Group boosted their price target on Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. Robert W. Baird upped their price target on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, Barclays upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price objective on the stock in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $151.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.